Stay updated on Nivolumab vs Placebo in Bladder Cancer Surgery Follow-up Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Placebo in Bladder Cancer Surgery Follow-up Clinical Trial page.

Latest updates to the Nivolumab vs Placebo in Bladder Cancer Surgery Follow-up Clinical Trial page
- Check4 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing Revision: v3.6.4. This indicates a new build or content-management update behind the page.SummaryDifference0.0%

- Check11 days agoChange DetectedIPD data-sharing details were added, including an IPD Sharing URL, access criteria, and policy language, along with the addition of key study documents (CSR, SAP, and Study Protocol). The record also shows updated recruitment status and a confirmed study completion date, with new locations listed.SummaryDifference1%

- Check18 days agoChange DetectedRevision: v3.6.4 was added to the page, replacing the previous Revision: v3.6.3. This indicates a minor update to the page's version metadata.SummaryDifference0.0%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, reflecting a small metadata update.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, reflecting a metadata/version update rather than a change to substantive content.SummaryDifference0.0%

- Check61 days agoChange DetectedAdded navigation and information sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment status update indicating no longer recruiting. The page also standardizes the label 'Intervention/Treatment' and updates the revision version reference.SummaryDifference0.2%

Stay in the know with updates to Nivolumab vs Placebo in Bladder Cancer Surgery Follow-up Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Placebo in Bladder Cancer Surgery Follow-up Clinical Trial page.